Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1

References

  1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 484: 1144–1148.

    Article  Google Scholar 

  2. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and agnogenic myeloid metaplasia. Cancer Cell 2005; 7: 387–397.

    CAS  Article  Google Scholar 

  3. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ‘atypical’ myeloproliferaive disorders and myelodysplastic syndromes. Blood 2005; 106: 1207–1209.

    CAS  Article  Google Scholar 

  4. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106: 3370–3373.

    CAS  Article  Google Scholar 

  5. Ohyashiki K, Aota Y, Akahane D, Gotoh A, Miyazawa K, Kimura Y et al. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 2005; 19: 2359–2360.

    CAS  Article  Google Scholar 

  6. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 17 – 1992. Repeated bouts of hematochezia in an 80-year-old hypertensive man. N Engl J Med 1992; 326: 1137–1146.

  7. Shaw GR . Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol 2005; 131: 180–184.

    PubMed  Google Scholar 

  8. Schmitt-Graeff A, Thiele J, Zuk I, Kvasnicka HM . Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity. Haematologica 2002; 87: 392–399.

    PubMed  Google Scholar 

Download references

Acknowledgements

We thank Nancy Lee Harris, MD at MGH, Harvard Medical School, for her valuable comments on WHO hematological malignancy classification. We also thank Jon Iafrate, MD at MGH, Harvard Medical School, for his technical support in JAK2 V617F mutation analysis.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S A Wang.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wang, S., Hasserjian, R., Loew, J. et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia 20, 1641–1644 (2006). https://doi.org/10.1038/sj.leu.2404316

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404316

Further reading

Search

Quick links